EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma

Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling

(2021) Hao Wang et al.   Cell Reports

First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose

(2021) Qingtang Lin et al.   Frontiers in Oncology

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

(2020) William D. Tap et al.   JOURNAL OF CLINICAL ONCOLOGY

IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.

(2020) Emanuela Palmerini et al.   JOURNAL OF CLINICAL ONCOLOGY

Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

(2020) Laura K. Donovan et al.   NATURE MEDICINE

Guidelines and definitions for research on epithelial–mesenchymal transition

(2020) Jing Yang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Matrix Rigidity Controls Epithelial-Mesenchymal Plasticity and Tumor Metastasis via a Mechanoresponsive EPHA2/LYN Complex

(2020) Laurent Fattet et al.   DEVELOPMENTAL CELL

Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights

(2020) Giulia Chiabotto et al.   Cancers

1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma

(2020) J.A. Ludwig et al.   ANNALS OF ONCOLOGY

Targeting isocitrate dehydrogenase mutations in cancer: emerging evidence and diverging strategies

(2020) Matthew S Waitkus et al.   CLINICAL CANCER RESEARCH

Targeting EphA2 in cancer

(2020) Ta Xiao et al.   Journal of Hematology & Oncology

EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer.

(2019) Giulia Martini et al.   MOLECULAR CANCER THERAPEUTICS

Secondary KIT mutations: the GIST of drug resistance and sensitivity

(2019) Andrea Napolitano et al.   BRITISH JOURNAL OF CANCER

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

(2019) Kohei Shitara et al.   Journal for ImmunoTherapy of Cancer

Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression

(2019) Rémy Nicolle et al.   Nature Communications

EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma

(2018) Silvia Garcia-Monclús et al.   INTERNATIONAL JOURNAL OF CANCER

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

(2018) Florence Duffaud et al.   LANCET ONCOLOGY

EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer

(2018) Qiu Peng et al.   Cell Death & Disease

DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma

(2017) Nathan C Sheffield et al.   NATURE MEDICINE

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers

(2017) W Song et al.   ONCOGENE

Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells

(2017) G-A Franzetti et al.   ONCOGENE

EphA2 is an epithelial cell pattern recognition receptor for fungal β-glucans

(2017) Marc Swidergall et al.   Nature Microbiology

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

(2016) Katherine R. Amato et al.   CANCER RESEARCH

Protein kinase A can block EphA2 receptor–mediated cell repulsion by increasing EphA2 S897 phosphorylation

(2016) Antonio Barquilla et al.   MOLECULAR BIOLOGY OF THE CELL

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

(2015) Giovanni Grignani et al.   LANCET ONCOLOGY

Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2

(2015) Yue Zhou et al.   Nature Communications

HER2 in Breast Cancer

(2014) Uma Krishnamurti et al.   ADVANCES IN ANATOMIC PATHOLOGY

Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System

(2014) Elisa Barile et al.   ChemMedChem

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC

(2014) Katherine R. Amato et al.   JOURNAL OF CLINICAL INVESTIGATION

Ephrin-Eph signaling in embryonic tissue separation

(2014) Francois Fagotto et al.   Cell Adhesion & Migration

Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis

(2013) Marnie Collins et al.   JOURNAL OF CLINICAL ONCOLOGY

EphA2 promotes epithelial–mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells

(2013) J Huang et al.   ONCOGENE

EphA2-Induced Angiogenesis in Ewing Sarcoma Cells Works through bFGF Production and Is Dependent on Caveolin-1

(2013) Miguel Sáinz-Jaspeado et al.   PLoS One

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Roles of EphA2 in Development and Disease

(2013) Jeong Park et al.   Genes

The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas

(2012) Elena Binda et al.   CANCER CELL

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

(2012) Kevin KH Chow et al.   MOLECULAR THERAPY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

(2011) G. Grignani et al.   ANNALS OF ONCOLOGY

EGFR Mutations and Lung Cancer

(2011) Gilda da Cunha Santos et al.   Annual Review of Pathology-Mechanisms of Disease

De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway

(2010) Raphaela Fritsche-Guenther et al.   HISTOPATHOLOGY

Review of mifamurtide in the treatment of patients with osteosarcoma

(2010) Leo Kager et al.   Therapeutics and Clinical Risk Management

Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome

(2009) Muhammad U. Jawad et al.   CANCER

EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt

(2009) Hui Miao et al.   CANCER CELL

EphA2 Reexpression Prompts Invasion of Melanoma Cells Shifting from Mesenchymal to Amoeboid-like Motility Style

(2009) M. Parri et al.   CANCER RESEARCH

Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited

(2009) Farideh Sabeh et al.   JOURNAL OF CELL BIOLOGY

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting

(2008) J. Wykosky et al.   MOLECULAR CANCER RESEARCH